Sowa-Rigpa Standards: From Formulations to Verifiable Drug Quality

Why in News?

The Ministry of Ayush announced on September 21 that a Sowa-Rigpa working group had begun work towards pharmacopoeias and formularies at its first meeting on September 18, 2026.

• The working group operates under the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H), which hosted the meeting in Ghaziabad.
• Its proposed work includes formularies, pharmacopoeias and related documents supporting regulatory implementation and quality assurance for Sowa-Rigpa drugs.
• The release places the exercise within the Drugs and Cosmetics Act, 1940 and its rules; it does not announce completed standards or a new drug approval.

• The policy question is how to convert documented formulations into consistent, testable product specifications that manufacturers and laboratories can apply.
• A quality benchmark addresses what a product contains and whether it meets requirements; a therapeutic claim requires evidence about what it does in patients.

UPSC Relevance

Prelims Relevance

• PCIM&H: subordinate office under the Ministry of Ayush.
• Pharmacopoeia: an official compendium of drug-quality standards.
• Formulary: a reference describing selected formulations, their composition and preparation.
• Monograph: a specification for an individual substance or preparation within a pharmacopoeia.
• Initiation versus notification: a working-group meeting does not itself bring completed new standards into force.

Mains Relevance

GS Paper 3

• Translating traditional pharmaceutical knowledge into reproducible quality specifications.

GS Paper 2

• Institutional capacity, evidence and accountability in drug regulation.

Essay

• Preserving knowledge while making claims open to verification.

Background and Context

What the new working group is being asked to do

The immediate development is an institutional start: experts will prepare documents that can support quality regulation, rather than announce a finished regulatory outcome.

• PCIM&H develops pharmacopoeias and formularies and acts as the Central Drug Testing-cum-Appellate Laboratory for Indian systems of medicine and homoeopathy. Its mandate connects written specifications with the practical task of evaluating drug samples.
• The Ayush announcement describes a step-wise action plan for Sowa-Rigpa documents. It does not supply final specifications, a completed publication, an implementation deadline or a list of newly approved treatments.
• The working group brings specialist knowledge into the standards process. Identifying a traditional preparation is only the starting point; a usable specification must communicate requirements consistently to people outside the originating practice setting.
• Statutory and non-statutory documents are both envisaged. Their roles differ: a technical reference can support implementation, but its existence alone does not establish that every statement within it has acquired binding legal force.
• For this development, the safe distinction is between work initiated and standards issued. The meeting began an organised exercise; subsequent documents and applicable legal steps will determine the requirements that manufacturers must follow.

Pharmacopoeia and formulary answer different questions

A formulation reference describes the preparation; a quality standard gives a basis for assessing material against specified requirements. Both are needed for consistent products.

• A formulary records selected preparations, including their ingredients and preparation method. In traditional-medicine practice, this helps establish which formulation is being discussed before its quality is assessed or its production is compared across manufacturers.
• A pharmacopoeia collects official drug-quality specifications. Its individual monographs provide a reference against which a substance or preparation can be assessed, helping laboratories move from a product name to defined examination requirements.
• The practical comparison is composition and preparation versus quality specification. A manufacturer needs to know what to prepare; a laboratory needs an appropriate basis for deciding whether the resulting sample meets the stated standard.
• These functions are complementary, not interchangeable. A detailed preparation description cannot by itself establish that every batch meets quality requirements, while testing requires clarity about the material or formulation being examined.
• The Commission’s mandate connects published standards with laboratory testing. Preparation references and quality specifications support that work; neither should be read as Sowa-Rigpa documents already completed by the new group.

What standardisation can establish, and what it cannot

The value of standardisation is a shared basis for checking products. Claims about patient benefit, clinical safety or implementation require their own supporting evidence.

• Quality consistency matters because a product name alone cannot demonstrate that different batches are equivalent in the characteristics a standard measures. Specified requirements make comparison possible without relying solely on the manufacturer’s description.
• Testing capacity determines whether a written benchmark can be used effectively. Laboratories need suitable methods, equipment and trained personnel; publishing a specification is not evidence that every marketed batch has been independently checked.
• Traceability links a test result to the particular sample and batch examined. As a governance principle, records help authorities investigate failures; an acceptable result should not be generalised automatically to unrelated products or batches.
• Clinical effectiveness asks whether an intervention produces meaningful benefit for a defined condition. Meeting product-quality requirements does not answer that question, and the working-group announcement reports no clinical findings that would justify treatment recommendations.
• Implementation claims also need verification. The release describes intended support for regulatory provisions; it does not establish universal compliance, completed inspections or improved patient outcomes. Those are results to assess after the relevant systems operate.

Way Forward

Make future standards usable and auditable

• Publish clear specifications and implementation status so manufacturers and testing laboratories can identify which requirements apply and when.
• Validate testing methods and strengthen laboratory capacity before treating publication as proof of effective quality assurance.
• Maintain batch records and traceability to connect identified failures with corrective action.
• Communicate quality compliance and clinical evidence separately so technical standards are not promoted as proof of therapeutic benefit.

Conclusion

• The Sowa-Rigpa exercise begins the work of connecting formulation knowledge with verifiable product-quality requirements. Its significance lies in developing shared references that manufacturers, laboratories and regulators can use, rather than in announcing a completed standard.
• In an answer, distinguish formulation description, quality verification and clinical evidence. They answer different questions. Strong regulation requires each claim to be supported at the appropriate level, with implementation assessed through evidence rather than an institutional announcement.

UPSC Practice Questions

Prelims MCQ 1

With reference to the Sowa-Rigpa standards initiative, consider the following statements:

1. PCIM&H operates under the Ministry of Ayush.
2. A formulary can describe the composition and preparation of selected formulations.
3. The first working-group meeting established the clinical effectiveness of all Sowa-Rigpa drugs.

How many of the above statements are correct?

(a) Only one (b) Only two (c) All three (d) None

Answer: (b) Only two

Explanation:

The first two statements are correct. The meeting initiated standards work; it neither completed the documents nor established clinical effectiveness.

Prelims MCQ 2

Which question is most directly addressed by a pharmacopoeial quality specification?

(a) Whether a product guarantees recovery in every patient (b) Whether every traditional treatment should replace existing care (c) Whether a sample meets defined requirements for the material or preparation (d) Whether a working-group meeting has completed all regulatory inspections

Answer: (c) Whether a sample meets defined requirements for the material or preparation

Explanation:

A pharmacopoeial specification supplies drug-quality requirements. Product conformity, clinical benefit and implementation outcomes must be evaluated separately.

UPSC Mains Questions

1. Explain how formularies and pharmacopoeias perform complementary functions in regulating traditional medicines.
2. Why is the publication of drug-quality standards insufficient to establish clinical effectiveness or successful regulatory implementation? Discuss.

Sources: PIB, Ministry of Ayush and PIB, PCIM&H mandate.

Frequently Asked Questions